We continue to estimate FY 2024 EBITDA to be in the range of $3,900,000,000 to $4,000,000,000 However, given the overall trends in the business and initial cost impacts from the incremental PCF sales, we see FY 2024 EBITDA at the low end of that range. As we said previously, we expect EBITDA to decline year over year in 2025 as a result of continued legacy declines, start up costs for PCF contracts and incremental transformation costs with a longer term goal of improving the broader cost structure. 2024 CapEx is expected to be in the range of $3,100,000,000 to $3,300,000,000 and cash interest in the range of $1,150,000,000 to $1,250,000,000 Lastly, we're raising our free our 2024 free cash flow guidance from $1,000,000,000 to $1,200,000,000 to $1,200,000,000 This guidance includes some incremental OpEx, CapEx and cash flows associated with our PCF sales growth as well as incremental spending to ultimately improve our cost structure and margins. And with that, I'll turn it back to Kate for closing remarks.